Xeljanz Lawsuit Signed Cases
If you want to grow your pharmaceutical practice, those Xeljianz has injured offer you an opportunity worth considering. The use of this popular drug increases the risk of severe, possibly fatal side effects. ZeroRisk Cases® can help you connect with injured former Xeljianz users looking for legal help.
What is Xeljanz?
Xeljanz treats moderate to severe rheumatoid arthritis, active psoriatic arthritis, and moderate to severe ulcerative colitis. Rheumatoid arthritis (RA) is a chronic inflammatory disease impacting joints, skin, eyes, lungs, the heart, and blood vessels. RA is an autoimmune disorder causing the immune system to attack the body’s healthy tissues. Psoriatic arthritis is a type of arthritis afflicting some with psoriasis. It causes joint stiffness, swelling, and pain. Ulcerative colitis is an inflammatory bowel disease causing ulcers and inflammation in the digestive tract.
How Does Xeljanz Work?
The drug comes in a pill in two formulations, Xeljanz and Xeljanz XR (extra release). The active ingredient is tofacitinib. It’s one of a group of drugs known as Janus kinase inhibitors or JAK inhibitors. JAKs are enzymes in the immune system and other cells that transmit chemical signals that change cell functions, including inflammation. When JAKs in immune cells are blocked, overly active immune processes that cause joint damage, pain, and swelling decrease.
Xeljianz decreases the amount of cytokines in the body. They’re a protein that regulates the immune system. They increase in response to infections, but too much causes inflammation and pain. When they decrease, the symptoms of the conditions Xeljianz treats improves. Xeljianz was approved by the Food and Drug Administration (FDA) in 2012.
Why is Xeljianz the Subject of Lawsuits?
The FDA completed a review of a large, randomized safety clinical trial of the drug. In 2021 they announced it found an increased risk of serious heart-related events (heart attack, stroke, blood clots, and death) and cancer in users.
Compared to patients treated with TNF blockers (drugs that suppress the immune system by blocking TNF, a substance that can cause inflammation) a higher rate of lymphomas (cancers impacting the lymph glands and cells of the immune system) was found in Xeljanz users. A higher rate of lung cancers was observed in current or past smokers treated with Xeljanz compared to those treated with TNF blockers. Current or past smokers had an additional increased risk of cancers in general.
What is the FDA Doing About Xeljianz?
It requires new and updated warnings for it and two other arthritis medicines that are also JAK inhibitors, Olumiant (baricitinib) and Rinvoq (upadacitinib). Xeljian’s boxed warning now includes information about the risks of heart-related severe events, cancer, blood clots, and death.
Health care professionals are told to consider the benefits and risks for the patient before starting or continuing Xeljian’s use. The FDA also limits approved use to patients who haven’t responded or cannot use one or more TNF blockers.
What Should Patients Using Xeljianz Do?
The FDA advises patients to discuss the drug with their physicians, especially those who:
- Smoke now or have in the past
- Had a heart attack, other heart problems, stroke, or blood clots in the past
These factors put people at higher risk for serious, potentially disabling, or fatal side effects.
Why Should You Take Xeljianz Cases?
Some of its users have become seriously ill because of this medication, and their rights to compensation should be protected. These lawsuits have started to be filed, so this is an opportunity to break new ground and make your practice known to others.
Xeljianz has been used since 2012 and widely marketed by its manufacturer, Pfizer. There are millions of Americans with the conditions the drug treats, so there could be a large number of potential clients:
- The federal Centers for Disease Control and Prevention estimates about 54.4 million Americans with some type of arthritis in 2015, with that number steadily increasing
- It’s estimated about a million Americans have psoriatic arthritis
- Inflammatory bowel disease (which includes Crohn’s disease) affects an estimated 3 million Americans
How We Can Help You Grow Your Xeljianz Litigation Practice
We have a division that focuses on generating leads for lawyers seeking mass tort litigation plaintiffs. Our energy and expertise is directed to getting our clients the best leads possible. Only one firm receives an inquiry, so the chances the person will retain a competing law firm is slim.
We focus our advertising efforts on TV, radio, organic SEO (Google, Bing, Yahoo), Google Maps, Google Ads, Bing, Facebook and Instagram, but depending on your ideal client profile, we may turn to other platforms. Unlike other mass tort ad agencies, we have experience with a number of different ad platforms, so we can use just the right one to get the job done. We focus on mobile marketing, utilizing Voice Search, to capture some of the best and highest converting leads.
We also use remarketing and behavioral targeting in our lead generation campaigns. Remarketing and behavioral targeting allow us to target the right people at the right time with the right message to get them on the phone.
Our latest technology utilizes our proprietary software that enables us to data mine information through third party vendors, resulting in cases where leads have been matched with their medical histories, diagnosis, drug prescription and treatments with exposure or usage of a caustic drug or chemical. This significantly reduces the cost of acquisition and provides a much higher value clients; one that has proof of usage or exposure; proof of diagnosis; and proof of treatment.
Get started before your competitors do. There’s only so many clients we can serve.
CONTACT US FOR A CUSTOM QUOTE.
CALL 833-937-6747 OR USE OUR REQUEST A QUOTE FORM.